Figures & data
Figure 1. Proportion of men with de novo metastatic castration sensitive prostate cancer in NPCR who received additional medical treatment; docetaxel, abiraterone, enzalutamide, or apalutamide together with androgen deprivation therapy. Data from NPCR and the Prescribed Drug Register on drug treatment delivered within six months from date of diagnosis for men with de novo metastatic castration sensitive prostate cancer diagnosed between 1 July 2018 and 31 March 2022.
Figure 2. Proportion of men in NPCR below age 80 with locally advanced prostate cancer who received radical treatment. Data available at www.npcr.se/RATTEN.
